Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in superior sulcus non-small cell lung cancer
NCT04465968Phase 3Not yet recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Sep 2020
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), Pancoast tumor, sponsored by National Cancer Center Hospital East. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)Pancoast tumor
Beyond the preview
Go deeper on NCT04465968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465968.